La chaîne d'options affiche les données clés des options sur actions de Clearmind Medicine à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Clearmind Medicine..

Clearmind Medicine (NASDAQ:CMND) Stock, Chaîne d'Options

Clearmind Medicine

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Clearmind Medicine Inc

Health Care

Press Releases

Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities

Penny Stocks

Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies

News

Legal

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

CMND

CSE:CMND

SPRC

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Artelo Biosciences

Aspire Biopharma Holdings, Inc. - Warrant

Aspire Biopharma Hldgs

CNS Pharma

China Pharma Holding

Evoke Pharma

Impact BioMedical

IM Cannabis

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

NLS Pharmaceutics

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

PainReform

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Reviva Pharmaceuticals Holdings, Inc. - Warrants

Reviva Pharmaceuticals

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

SciSparc

60 Degrees Pharmaceuticals, Inc. - Common Stock

Comments

Clearmind Medicine

Clearmind Medicine (CMND) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL